Exogenous ketone therapy for heart failure: A review
- Authors: Aksenova Y.O.1, Osmolovskaya Y.F.1, Zhirov I.V.1,2, Beniashvili A.G.3, Morozova M.A.3, Tereshchenko S.N.1
-
Affiliations:
- Chazov National Medical Research Center of Cardiology
- Russian Medical Academy of Continuous Professional Education
- Mental Health Science Center
- Issue: Vol 25, No 1 (2023): Cardiovascular diseases
- Pages: 46-51
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/131640
- DOI: https://doi.org/10.26442/20751753.2023.1.202174
- ID: 131640
Cite item
Full Text
Abstract
Heart failure is of major clinical and economic importance and remains a major public health problem worldwide. Despite existing treatment approaches, morbidity and mortality in these patients remains high. The progression of heart failure is accompanied by an increase in the metabolism of ketone bodies. The use of exogenous ketones may become a new therapeutic approach to increase cardiac efficiency, reduce energy deficit and improve cardiac function in patients with heart failure. The review presents the available data on ketone body metabolism in patients with heart failure, preclinical and clinical studies demonstrating the beneficial effects of exogenous ketone therapy in animal models and human studies with heart failure, and describes the potential pros and cons of using this therapeutic approach.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Yulia O. Aksenova
Chazov National Medical Research Center of Cardiology
Email: bonisana@mail.ru
ORCID iD: 0000-0002-6546-2535
Medical Resident
Russian Federation, MoscowYulia F. Osmolovskaya
Chazov National Medical Research Center of Cardiology
Email: bonisana@mail.ru
ORCID iD: 0000-0002-7827-2618
Department Head
Russian Federation, MoscowIgor V. Zhirov
Chazov National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education
Author for correspondence.
Email: izhirov@mail.ru
ORCID iD: 0000-0002-4066-2661
D. Sci. (Med.)
Russian Federation, Moscow; MoscowAllan G. Beniashvili
Mental Health Science Center
Email: izhirov@mail.ru
ORCID iD: 0000-0002-5149-3760
Cand. Sci. (Med.)
Russian Federation, MoscowMargarita A. Morozova
Mental Health Science Center
Email: izhirov@mail.ru
ORCID iD: 0000-0002-7847-2716
D. Sci. (Med.), Prof.
Russian Federation, MoscowSergey N. Tereshchenko
Chazov National Medical Research Center of Cardiology
Email: izhirov@mail.ru
ORCID iD: 0000-0001-9234-6129
D. Sci. (Med.), Prof.
Russian Federation, MoscowReferences
- Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: A report from the American Heart Association. Circulation. 2016;133:e38-60. doi: 10.1161/CIR.0000000000000350
- Neubauer S. The failing heart – an engine out of fuel. N Engl J Med. 2007;356:1140-151. doi: 10.1056/NEJMra063052
- Selvaraj S, Kelly DP, Kenneth B. Margulies Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure. Circulation. 2020;141(22):1800-12. doi: 10.1161/CIRCULATIONAHA.119.045033
- Bedi KC Jr, Snyder NW, Brandimarto J, et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation. 2016;133:706-16. doi: 10.1161/CIRCULATIONAHA.115.017545
- Lopaschuk GD, Karwi QG, Tian R, et al. Cardiac Energy Metabolism in Heart Failure. Circ Res. 2021;128(10):1487-513. doi: 10.1161/CIRCRESAHA.121.318241
- Takahara S, Soni S, Maayah ZH, et al. Ketone therapy for heart failure: Current evidence for clinical use. Cardiovasc Res. 2022;118:97-87. doi: 10.1093/cvr/cvab068
- Puchalska P, Crawford PA. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab. 2017;25:262-84. doi: 10.1016/j.cmet.2016.12.022
- Karwi QG, Uddin GM, Ho KL, Lopaschuk GD. Loss of metabolic flexibility in the failing heart. Front Cardiovasc Med. 2018;5:68. doi: 10.3389/fcvm.2018.00068
- Nielsen R, Moller N, Gormsen LC, et al. Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients. Circulation. 2019;139:2129-41. doi: 10.1161/CIRCULATIONAHA.118.036459
- Horton JL, Davidson MT, Kurishima C, et al. The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. JCI Insight. 2019;4:e124079. doi: 10.1172/jci.insight.124079
- Pietschner R, Kolwelter J, Bosch A, et al. Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. Cardiovasc Diabetol. 2021;20:219. doi: 10.1186/s12933-021-01410-7
- McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008. doi: 10.1056/NEJMoa1911303
- Murthy MS, Pande SV. Malonyl-CoA binding site and the overt carnitine palmitoyltransferase activity reside on the opposite sides of the outer mitochondrial membrane. Proc Natl Acad Sci U S A. 1987;84(2):378-82. doi: 10.1073/pnas.84.2.378
- Hui S, Ghergurovich JM, Morscher RJ, et al. Glucose feeds the tca cycle via circulating lactate. Nature. 2017;551:115-8. doi: 10.1038/nature24057
- Ho KL, Karwi QG, Wagg C, et al. Ketones can become the major fuel source for the heart but do not increase cardiac efficiency. Cardiovasc Res. 2020. doi: 10.1093/cvr/cvaa143
- Evans M, McClure TS, Koutnik AP, Egan B. Exogenous Ketone Supplements in Athletic Contexts: Past, Present, and Future. Sports Med. 2022;52(Suppl. 1):25-67. doi: 10.1007/s40279-022-01756-2
- Balasse EO, Féry F. Ketone body production and disposal: effects of fasting, diabetes, and exercise. Diabetes Metab Rev. 1989;5:247-70. doi: 10.1002/dmr.5610050304
- Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev. 1999;15:412-26. doi: 10.1002/(SICI)1520-7560(199911/12)15:6<412::AID-DMRR72>3.0.CO;2-8
- Fukao T, Lopaschuk GD, Mitchell GA, et al. Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry. Prostaglandins Leukot Essent Fat Acids. 2004;70:243-51. doi: 10.1016/j.plefa.2003.11.001
- Halestrap AP, Wilson MC. The monocarboxylate transporter family – role and regulation. IUBMB Life. 2012;64(2):109-19. doi: 10.1002/iub.572
- Fukao T, Song XQ, Mitchell GA, et al. Enzymes of ketone body utilization in human tissues: protein and messenger RNA levels of succinyl-coenzyme A (CoA):3-ketoacid CoA transferase and mitochondrial and cytosolic acetoacetyl-CoA thiolases. Pediatr Res. 1997;42(4):498-502. doi: 10.1203/00006450-199710000-00013
- Cox PJ, Kirk T, Ashmore T, et al. Nutritional ketosis alters fuel preference and thereby endurance performance in athletes. Cell Metab. 2016;24:256-68. doi: 10.1016/j.cmet.2016.07.010
- Neubauer S. The failing heart – an engine out of fuel. N Engl J Med. 2007;356(11):1140-51. doi: 10.1056/NEJMra063052
- Zhou B, Tian R. Mitochondrial dysfunction in pathophysiology of heart failure. J Clin Invest. 2018;128(9):3716-26. doi: 10.1172/JCI120849
- Shanmugam G, Wang D, Gounder SS, et al. Reductive stress causes pathological cardiac remodeling and diastolic dysfunction. Antioxid Redox Signal. 2020;32:1293-312. doi: 10.1089/ars.2019.7808
- Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol. 2011;301:H2181-90. doi: 10.1152/ajpheart.00554.2011
- O’Rourke B, Ashok D, Liu T. Mitochondrial Ca(2+) in heart failure: Not enough or too much? J Mol Cell Cardiol. 2020;151:126-34. doi: 10.1016/j.yjmcc.2020.11.014
- Sheeran FL, Angerosa J, Liaw NY, et al. Adaptations in Protein Expression and Regulated Activity of Pyruvate Dehydrogenase Multienzyme Complex in Human Systolic Heart Failure. Oxid Med Cell Longev. 2019;2019:4532592. doi: 10.1155/2019/4532592
- McCommis KS, Kovacs A, Weinheimer CJ, et al. Nutritional Modulation of Heart Failure in Mitochondrial Pyruvate Carrier-Deficient Mice. Nat Metab. 2020;2(11):1232-47. doi: 10.1038/s42255-020-00296-1
- Bedi KC Jr, Snyder NW, Brandimarto J, et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation. 2016;133:706-16. doi: 10.1161/CIRCULATIONAHA.115.017545
- Aubert G, Martin OJ, Horton JL, et al. The failing heart relies on ketone bodies as a fuel. Circulation. 2016;133:698-705. doi: 10.1161/CIRCULATIONAHA.115.017355
- Cox PJ, Kirk T, Ashmore T, et al. Nutritional ketosis alters fuel preference and thereby endurance performance in athletes. Cell Metab. 2016;24:256-68. doi: 10.1016/j.cmet.2016.07.010
- Gormsen LC, Svart M, Thomsen HH, et al. Ketone body infusion with 3-hydroxybutyrate reduces myocardial glucose uptake and increases blood flow in humans: A positron emission tomography study. J Am Heart Assoc. 2017;6(3):e005066. doi: 10.1161/JAHA.116.005066
- Nielsen R, Moller N, Gormsen LC, et al. Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients. Circulation. 2019;139:2129-41. doi: 10.1161/CIRCULATIONAHA.118.036459
- Volek JS, Phinney SD. The Art and Science of Low Carbohydrate Performance: A Revolutionary Program to Extend Your Physical and Mental Performance Envelope. Miami, FL: Beyond Obesity LLC, 2012.
- Shaw DM, Merien F, Braakhuis A, et al. The effect of 1,3-butanediol on cycling time-trial performance. Int J Sport Nutr Exerc Metab. 2019;29:466-73. doi: 10.1123/ijsnem.2018-0284
- Scott BE, Laursen PB, James LJ, et al. The effect of 1,3-butanediol and carbohydrate supplementation on running performance. J Sci Med Sport. 2019;22:702-6. doi: 10.1016/j.jsams.2018.11.027
- Cunnane SC, Courchesne-Loyer A, Vandenberghe C, et al. Can ketones help rescue brain fuel supply in later life? Implications for cognitive health during aging and the treatment of Alzheimer’s disease. Front Mol Neurosci. 2016;9:53. doi: 10.3389/fnmol.2016.00053
- Harvey CJC, Schofield GM, Williden M, McQuillan JA. The effect of medium chain triglycerides on time to nutritional ketosis and symptoms of keto-induction in healthy adults: a randomised controlled clinical trial. J Nutr Metab. 2018;2018:2630565. doi: 10.1155/2018/2630565
- Stubbs BJ, Cox PJ, Kirk T, et al. Gastrointestinal effects of exogenous ketone drinks are infrequent, mild, and vary according to ketone compound and dose. Int J Sport Nutr Exerc Metab. 2019;29:596-603. doi: 10.1123/ijsnem.2019-0014
- Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-24. doi: 10.1056/NEJMoa2022190
- Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512-7. doi: 10.1038/nm.3828
- Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium–glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65(5):1190-5. doi: 10.2337/db15-1356
- Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors. J Am Coll Cardiol Basic Transl Sci. 2020;5:632-44. doi: 10.1016/j.jacbts.2020.02.004
- Vishwanath S, Qaderi V, Steves CJ, et al. Cognitive Decline and Risk of Dementia in Individuals With Heart Failure: A Systematic Review and Meta-analysis. J Card Fail. 2022;28(8):1337-48. doi: 10.1016/j.cardfail.2021.12.014
- Yap NLX, Kor Q, Teo YN, et al. Prevalence and incidence of cognitive impairment and dementia in heart failure – A systematic review, meta-analysis and meta-regression. Hellenic J Cardiol. 2022;67:48-58. doi: 10.1016/j.hjc.2022.07.005
- Poff AM, Moss S, Soliven M, D'Agostino DP. Ketone Supplementation: Meeting the Needs of the Brain in an Energy Crisis. Front Nutr. 2021;8:783659. doi: 10.3389/fnut.2021.783659